A medicine approved in Europe or the United States is not yet a medicine available to a patient in Dubai, Riyadh or Muscat. Between global approval and the hospital shelf sit registration, pricing, formulary listing, tender award and import. Each step is necessary. Each delay has a human consequence.
The clinical cost of waiting
When therapy access is delayed, patients face ten well-recognised risks:
Disease progression – conditions advance while treatment is unavailable.
Irreversible damage – some organ or neurological loss cannot be recovered.
Organ failure – untreated chronic disease can end in dialysis, transplant or ventilation.
Increased mortality – in oncology, rare disease and infection, time is survival.
Treatment resistance – suboptimal alternatives can drive resistance.
Severe complications – uncontrolled disease generates avoidable events.
Emergency hospitalisation – acute admissions replace planned care.
Reduced survival – later-line treatment often delivers less benefit.
Permanent disability – delayed intervention can mean lifelong impairment.
Poorer prognosis – outcomes worsen the later effective treatment starts.
Where delays really come from
In our experience, most delays are not caused by regulators. They come from incomplete dossiers, inconsistent documents across markets, missing legalisations, late Arabic labelling, unclear pricing strategy, and tender submissions that miss a technical requirement.
How HERMS shortens the path
HERMS plans registration, pricing and tender readiness as one sequence, not three separate projects. We audit dossiers before submission, align artwork and Arabic labelling early, and map tender calendars against expected approval dates so a product is ready when the purchasing window opens.
Planning a GCC launch? Speak to HERMS about a readiness review before your first submission. info@hermsglobal.com | +971 55 600 8944 Contact HERMS →